Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio discloses time-based vesting stock option and RSU inducement grants for six new hires under its 2023 Inducement Plan.

Rhea-AI Summary

Vor Bio (VOR) granted inducement equity awards to six newly hired employees on September 1, 2026 under its 2023 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).

The awards consist of stock options to purchase an aggregate of 83,600 shares and RSUs covering 17,900 shares of common stock. The options have a ten-year term and an exercise price of $22.64, equal to the closing price on the grant date. Both options and RSUs vest over four years, with 25% vesting after 12 months and the remainder vesting over the following 36 months, subject to continued employment and the applicable award agreements.

Market Context

The September 1 conference-participation announcement preceded a 0.71% 24-hour move, adding a recent...

Analysis

The September 1 conference-participation announcement preceded a 0.71% 24-hour move, adding a recent neutral-news reference. Investors can weigh this grant against the effective resale registration and its absence of company proceeds.

Key Figures

Stock options: 83,600 shares Restricted stock units: 17,900 shares Recipients: 6 employees +4 more

7 metrics

Stock options 83,600 shares Granted to six newly hired employees

Restricted stock units 17,900 shares Granted to six newly hired employees

Recipients 6 employees Newly hired employees

Exercise price $22.64 per share Equal to the closing price on the grant date

Option term 10 years Stock options

Option vesting 4 years 25% after 12 months and remainder monthly over 36 months

RSU vesting 4 years 25% after 12 months and remainder quarterly over 36 months

Historical Context

5 past events · Latest: Sep 01 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 01	Conference participation	Neutral	+0.7%	Management announced participation in several September investor conferences.
Aug 11	Quarterly earnings	Positive	+0.9%	Reported second-quarter results and continued Phase 3 development progress.
Aug 03	Inducement grant	Neutral	+3.9%	Granted options and RSUs to five newly hired employees.
Jul 07	Board appointment	Positive	+1.0%	Appointed David Zaccardelli to the board of directors.
Jul 02	Inducement grant	Neutral	-2.4%	Granted inducement equity awards to seven newly hired employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Inducement-grant announcements produced mixed historical reactions, with one positive and one negative 24-hour move.

Key Terms

rsus, nasdaq listing rule 5635(c)(4), inducement plan, exercise price

4 terms

rsus financial

"restricted stock units (“RSUs”) representing the right to receive"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement plan financial

"under the Vor Biopharma Inc. 2023 Inducement Plan"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

exercise price financial

"an exercise price of $22.64 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 83,600 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 17,900 shares of Vor Bio’s common stock to 6 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

The stock options have a ten-year term, and an exercise price of $22.64 per share, which is equal to the closing price of Vor Bio’s common stock on the grant date of the stock options. The options will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The RSUs will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting quarterly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The options and RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an award agreement covering the grants.

About Vor Bio

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com

Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

FAQ

What equity awards did Vor Bio (VOR) grant as inducement to new employees?

Vor Bio granted stock options to purchase an aggregate of 83,600 shares of common stock and RSUs representing 17,900 shares to six newly hired employees as material inducements to employment under its 2023 Inducement Plan.

What is the exercise price and term of the new Vor Bio (VOR) stock options?

The stock options have a term of ten years and an exercise price of $22.64 per share, which equals the closing price of Vor Bio’s common stock on the September 1, 2026 grant date.

How do the Vor Bio (VOR) inducement stock options vest for new hires?

The stock options vest over four years: 25% of the shares vest after 12 months, and the remaining 75% vest in equal monthly installments over the following 36 months, subject to continued employment.

What is the vesting schedule for the Vor Bio (VOR) inducement RSUs?

The RSUs vest over four years: 25% of the shares vest after 12 months, and the remaining 75% vest in equal quarterly installments over the following 36 months, contingent on the employees’ continued employment.

Under which plan were Vor Bio’s (VOR) inducement grants made and what Nasdaq rule applies?

The stock options and RSUs were granted under the Vor Biopharma 2023 Inducement Plan and are described as material inducements to employment made in accordance with Nasdaq Listing Rule 5635(c)(4).